Subtopic Deep Dive
Pharmacological Prophylaxis of Migraine
Research Guide
What is Pharmacological Prophylaxis of Migraine?
Pharmacological prophylaxis of migraine involves preventive drug treatments using agents like beta-blockers, topiramate, CGRP monoclonal antibodies, and onabotulinumtoxinA to reduce attack frequency in adults and pediatrics based on randomized controlled trials.
Guidelines establish divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol as effective for episodic migraine prevention (Silberstein et al., 2012, 855 citations). OnabotulinumtoxinA demonstrated efficacy in chronic migraine through PREEMPT trials (Aurora et al., 2010, 1011 citations; Dodick et al., 2010, 949 citations). High-dose riboflavin reduced migraine frequency in RCTs (Schoenen et al., 1998, 533 citations). Over 10 key papers exceed 500 citations each.
Why It Matters
Preventive treatments cut migraine attacks by 50% or more, enhancing quality of life for 15% of adults affected (Silberstein et al., 2000, 1354 citations). OnabotulinumtoxinA reduced headache days by 8.4 in chronic migraine patients across PREEMPT trials (Dodick et al., 2010, 949 citations). Galcanezumab prevented episodic migraines effectively in phase 3 trials (Stauffer et al., 2018, 546 citations). Guidelines guide clinicians to optimize regimens, reducing disability and healthcare costs (Evers et al., 2009, 882 citations).
Key Research Challenges
Optimizing Drug Selection
Choosing between beta-blockers, topiramate, and CGRP agents requires balancing efficacy, side effects, and patient profiles from heterogeneous RCTs. Silberstein et al. (2012) reviewed 29 Class I/II studies establishing topiramate and propranolol efficacy but noted variability in response rates. Personalized regimens remain underdeveloped.
Pediatric Prophylaxis Efficacy
Limited RCTs address prophylaxis safety in children, with adult data like topiramate not fully extrapolating. Ayata et al. (2006) linked prophylaxis to cortical spreading depression suppression but pediatric trials lag. Dosing optimization faces ethical barriers.
Chronic vs Episodic Differentiation
Distinguishing prophylaxis needs for episodic versus chronic migraine complicates treatment; PREEMPT trials showed onabotulinumtoxinA superior for chronic cases (Aurora et al., 2010). Guidelines like Evers et al. (2009) provide recommendations but lack unified thresholds. Long-term adherence challenges persist.
Essential Papers
Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) [RETIRED]
Stephen D. Silberstein · 2000 · Neurology · 1.4K citations
Mission statement
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
SK Aurora, DW Dodick, CC Turkel et al. · 2010 · Cephalalgia · 1.0K citations
Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Metho...
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
David W. Dodick, Catherine C. Turkel, Ronald E. DeGryse et al. · 2010 · Headache The Journal of Head and Face Pain · 949 citations
( Headache 2010;50:921‐936) Objective.— To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX ® ) as headache prophylaxis in adults with chronic migraine. Background.— Chron...
EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force
Stefan Evers, Judit Áfra, Achim Frese et al. · 2009 · European Journal of Neurology · 882 citations
Background: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients’ quality of life. Objectives: To give evidence‐based or expert recommendations...
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
Stephen D. Silberstein, Starr Holland, F. G. Freitag et al. · 2012 · Neurology · 855 citations
The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol,...
Migraine: Multiple Processes, Complex Pathophysiology
Rami Burstein, Rodrigo Noseda, David Borsook · 2015 · Journal of Neuroscience · 799 citations
Migraine is a common, multifactorial, disabling, recurrent, hereditary neurovascular headache disorder. It usually strikes sufferers a few times per year in childhood and then progresses to a few t...
Suppression of cortical spreading depression in migraine prophylaxis
Cenk Ayata, Hongwei Jin, Chiho Kudo et al. · 2006 · Annals of Neurology · 573 citations
Abstract Objective Topiramate, valproate, propranolol, amitriptyline, and methysergide have been widely prescribed for migraine prophylaxis, but their mechanism or site of action is uncertain. Cort...
Reading Guide
Foundational Papers
Start with Silberstein (2000, 1354 citations) for evidence-based guidelines, then Silberstein (2012, 855 citations) update establishing topiramate/propranolol efficacy, followed by Evers (2009, 882 citations) EFNS recommendations for prophylaxis hierarchy.
Recent Advances
Study Stauffer (2018, 546 citations) on galcanezumab for episodic prevention, American Headache Society (2018, 567 citations) position on new treatments integrating CGRP agents.
Core Methods
RCTs assess ≥50% responder rates and headache days reduction; PREEMPT used pooled double-blind phases (Dodick 2010); riboflavin RCT compared 400mg vs placebo (Schoenen 1998); CSD suppression models topiramate action (Ayata 2006).
How PapersFlow Helps You Research Pharmacological Prophylaxis of Migraine
Discover & Search
Research Agent uses searchPapers to query 'topiramate migraine prophylaxis RCTs' retrieving Silberstein et al. (2012), then citationGraph maps 855 citing papers and findSimilarPapers uncovers riboflavin trials like Schoenen et al. (1998). exaSearch scans 250M+ OpenAlex papers for pediatric prophylaxis gaps.
Analyze & Verify
Analysis Agent applies readPaperContent to PREEMPT trials (Dodick et al., 2010), verifyResponse with CoVe cross-checks headache day reductions against GRADE Level A evidence, and runPythonAnalysis computes meta-analysis effect sizes from 29 RCTs in Silberstein et al. (2012) using pandas for 50% reduction statistics.
Synthesize & Write
Synthesis Agent detects gaps in chronic migraine personalization post-Evers et al. (2009) guidelines, flags contradictions between topiramate efficacy and side effects; Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 10+ papers, latexCompile for polished reviews, and exportMermaid for prophylaxis decision trees.
Use Cases
"Meta-analyze topiramate vs propranolol efficacy from RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas forest plot of effect sizes from Silberstein 2012) → researcher gets CSV of pooled 50% responder rates with p-values.
"Draft LaTeX guideline update on CGRP prophylaxis"
Synthesis Agent → gap detection (post-Stauffer 2018) → Writing Agent → latexEditText + latexSyncCitations (Evers 2009, Dodick 2010) + latexCompile → researcher gets PDF with cited tables and figures.
"Find code for migraine prophylaxis trial simulators"
Research Agent → paperExtractUrls (Ayata 2006 CSD model) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts modeling topiramate suppression effects.
Automated Workflows
Deep Research workflow synthesizes 50+ prophylaxis papers into structured GRADE-graded reports, chaining searchPapers → citationGraph → runPythonAnalysis for meta-stats on PREEMPT data. DeepScan's 7-step analysis verifies onabotulinumtoxinA claims from Aurora et al. (2010) with CoVe checkpoints and statistical tests. Theorizer generates hypotheses on riboflavin mechanisms from Schoenen et al. (1998) literature.
Frequently Asked Questions
What defines pharmacological prophylaxis of migraine?
Preventive drug therapy using beta-blockers, topiramate, propranolol, and onabotulinumtoxinA to lower attack frequency by ≥50% in RCTs (Silberstein et al., 2012).
What are key methods in prophylaxis studies?
Double-blind RCTs measure migraine days, responder rates; PREEMPT trials used onabotulinumtoxinA 155U every 12 weeks versus placebo (Dodick et al., 2010).
What are major papers?
Silberstein (2000, 1354 citations) guidelines; Aurora (2010, 1011 citations) and Dodick (2010, 949 citations) PREEMPT; Silberstein (2012, 855 citations) update lists topiramate effective.
What open problems exist?
Pediatric dosing, chronic-episodic thresholds, and personalization beyond topiramate/propranolol lack RCTs; mechanisms like CSD suppression need validation (Ayata et al., 2006).
Research Migraine and Headache Studies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Pharmacological Prophylaxis of Migraine with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Migraine and Headache Studies Research Guide